{"filing":{"accession_number":"0001193125-26-346817","cik":"0001598646","ticker":"NERV","company_name":"Minerva Neurosciences, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-10","primary_document":"d116503d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1598646/000119312526346817/d116503d8k.htm"},"events":[{"id":27159,"run_id":24737,"accession_number":"0001193125-26-346817","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Anthony Aliquo was appointed Chief Accounting Officer and principal accounting officer effective August 10, 2026, representing a material promotion from Vice President, Controller. While the filing also discloses that Fred Ahlholm ceased serving as principal accounting officer (a secondary change), the principal disclosed action centers on Aliquo's appointment to a named executive officer role. The appointment is accompanied by salary and bonus increases, confirming its significance.","company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28570,"accession_number":"0001193125-26-346817","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Anthony Aliquo was appointed Chief Accounting Officer and principal accounting officer effective August 10, 2026, representing a material promotion from Vice President, Controller. While the filing also discloses that Fred Ahlholm ceased serving as principal accounting officer (a secondary change), the principal disclosed action centers on Aliquo's appointment to a named executive officer role. The appointment is accompanied by salary and bonus increases, confirming its significance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:08:49.098132+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28570,"accession_number":"0001193125-26-346817","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Anthony Aliquo was appointed Chief Accounting Officer and principal accounting officer effective August 10, 2026, representing a material promotion from Vice President, Controller. While the filing also discloses that Fred Ahlholm ceased serving as principal accounting officer (a secondary change), the principal disclosed action centers on Aliquo's appointment to a named executive officer role. The appointment is accompanied by salary and bonus increases, confirming its significance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:08:49.098132+00:00","company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","filing_date":"2026-08-12"}]}